Jane Street
IDXG

Jane Street’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Jane Street’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,369
Closed -$36K – 6127
2018
Q3 		$36K Buy
+2,369
New +$28.5K ﹤0.01% 4952

Other funds holding IDXG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WP
WealthSource Partners San Luis Obispo, California $1.54B AUM 16.68% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Jane Street's IDXG Position: Q4 2018 in Review

Jane Street sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q4 2018, closing a stake of 2,369 shares — an estimated $36K sold.

Jane Street first reported a position in IDXG in Q3 2018 and held it in 1 quarter. The position peaked at $36K in Q3 2018. 20 funds tracked by Wall St. Rank hold IDXG as of Q4 2018.

  • Jane Street reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Jane Street sold 2,369 Interpace Biosciences, Inc. Common Stock shares in Q4 2018, an estimated $36K.
  • Jane Street first reported a position in Interpace Biosciences, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Jane Street's Interpace Biosciences, Inc. Common Stock position peaked at $36K in Q3 2018.
  • 20 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q4 2018.

Based on Jane Street's 13F filing for Q4 2018, filed 15 Feb 2019.